Amgen is a leading human therapeutics company in the biotechnology industry. Amgen (NASDAQ: AMGN) discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one the first companies to realize the new science's promise by bringing novel medicines from lab to manufacturing plant to patient. Amgen therapeuticals have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses.

Headquartered in Southern California and with offices in more than 35 countries, Amgen has about 17.500 staff members worldwide. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Amgen is currently conducting extensive research programs in inflammation, metabolic disorders and osteoporosis, neurology, oncology and hematology with more than 50 products in the development pipeline. Being science-based in one of the Amgen core values and the essence of our culture. Understanding human biology and the role that genes, and the proteins expressed by them, play in the disease process is the cornerstone of our method. Changing the practice of medicine for the benefit of patients is our ultimate objective.

Amgen Belgium was established in 1990. With now nearly 100 staff members, Amgen Belgium encompasses a wide range of business activities from clinical development to commercial operations. The contribution of Amgen Belgium in clinical research is high: in 2008, Amgen Belgium participated to 56 studies, meaning that nearly half of Amgen staff was employed in R&D. In 2007, 2008 and 2009, Amgen was named amongst the 'Best Companies to Work For' in Belgium, as determined by the Vlerick Management School.